Bertrand Damour has 20 years’ international management experience and a successful track record across the biotech industry in Europe and US. He was previously CEO at the US proteomics company GeneProt Inc.; Mind NRG, a Swiss biotech in the field of CNS (which was acquired by Minerva Neurosciences (NASDAQ: NERV); OncoEthix, a Swiss based oncology company in the field of epigenetics, (which was acquired by Merck & Co. (NYSE: MRK) for US$375 million; and more recently at Synthena AG, a company developing Oligonucleotide based therapeutics for the treatment of genetic neuro muscular diseases. Prior to this, Bertrand worked in the banking industry and gained extensive experience in corporate transactions, including M&A, LBOs and IPOs while at J.P. Morgan, Rabobank International , Bankers Trust and Deutsche Bank in New York and London.
He graduated from the J.L. Kellogg Graduate School of Management at Northwestern University with an MBA degree in Finance and Statistics. He holds a Master of Engineering degree in Physics from the Institut des Sciences de la Matière et du Rayonnement (ISMRA) and a Master’s degree from the Institut d’Administration des Entreprises (IAE).